Phase 3 Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus

Conditions: Type 2 Diabetes Mellitus Interventions: Drug: TG103; Drug: Placebo Sponsors: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. Not yet recruiting

https://clinicaltrials.gov/study/NCT06258148

Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials